US Equities insigtX

Rein Therapeutics Reports Positive Lung Function Trends in Blinded Phase 2 RENEW Data

33% of evaluable patients showed improvement in forced vital capacity from baseline at Week 12 FVC changes from baseline to Week 12 ranged from an improvement of 338…

Published
Market
US Equities
Source
insigtX

33% of evaluable patients showed improvement in forced vital capacity from baseline at Week 12
FVC changes from baseline to Week 12 ranged from an improvement of 338 mL to a decline of 349 mL
Low discontinuation rates and favorable safety and tolerability profile observed in both placebo and treatment groups, with no serious adverse events related to study treatment
Study is 75% enrolled with 90 patients randomized to date; on track to report topline data in 2027

AUSTIN, Texas, November 16, 2026—Rein Therapeutics, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan lung disease and fibrotic indications, today announced preliminary blinded twelve-week observations from its ongoing Phase 2 RENEW trial evaluating its lead candidate, LTI-03, in patients with idiopathic pulmonary fibrosis. The company also reported third quarter financial results for the period ended September 30, 2026.

"During the third quarter, we continued to make rapid progress in the Phase 2 RENEW trial of LTI-03, driven by strong enrollment and investigator enthusiasm. As we continue to enroll patients in the study, today's blinded observations of the data show encouraging lung function trends and a favorable safety and tolerability profile across the study population, which reinforces our confidence that LTI-03 has the potential to deliver a differentiated clinical and safety profile for patients with significant unmet need. We remain committed to advancing the study to completion and look forward to reporting unblinded topline data in 2027," said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics.

Third Quarter 2026 and Recent Business Updates
Clinical Update
The RENEW study is a randomized, placebo-controlled Phase 2 trial evaluating inhaled LTI-03 in patients with IPF. The trial remains blinded while enrollment continues. The preliminary analysis included 24 patients with evaluable baseline and Week 12 forced vital capacity measurements. Blinded results were as expected; Week 12 FVC changes showed an encouraging distribution: At Week 12, preliminary blinded lung function observations included: 33% of patients had improved FVC from baseline. 46% of patients had FVC declines of no more than 5.7%, a threshold below which some studies suggest the likelihood of progression to lung transplant or death increases by more than 2-fold. 21% of patients had FVC declines greater than 5.7% from baseline. These observations represent pooled results from patients randomized to either placebo or one of two dose levels of LTI-03. Treatment assignment remains blinded, and these findings cannot establish treatment effect or enable comparisons between LTI-03 and placebo.

Figure 1: Blinded, pooled sponsor data. N=24: participants with Week 12 FVC results. FVC change from baseline to Week 12 calculated as a percentage of each participant's own baseline. Baseline calculated as the average of the qualifying screening and Day 1 pre-dose values. Groupings are descriptive and not pre-specified. These thresholds are used to describe the distribution of blinded, pooled data; they do not predict outcomes for RENEW participants or demonstrate treatment effect. The 5.7% threshold is derived from a meta-analysis of individual participant data from placebo groups across 12 IPF trial cohorts, where a relative FVC decline of greater than 5.7% over 3 months was the threshold that best distinguished higher mortality risk. Under the more stringent 5% threshold, 75% of patients improved or declined by less than 5%. The bar chart ranges from the largest individual gain to the largest individual decline in Week 12 FVC: it is a full range, not a confidence interval. Not drawn to scale. These are individual participant values and do not demonstrate treatment effect.

Favorable safety and tolerability profile: Preliminary blinded safety observations from the ongoing RENEW trial indicate a favorable safety and tolerability profile. As of the interim data cutoff, no serious adverse events related to study treatment were reported. Adverse events were primarily mild or moderate in severity, with cough being the most frequently reported adverse event and generally mild in nature. Discontinuation rates were low, with 92% of enrolled participants remaining in or having completed the study. The trial remains blinded, and the safety and tolerability of specific treatments will be further characterized as more data become available.

Topline data expected in 2027: As of November, Rein has completed 75% of the trial's planned enrollment, with 90 of approximately 120 patients randomized across the United States, United Kingdom, Australia, Germany, and Poland. Enrollment is ahead of schedule, and the company remains on track to report topline data in 2027.

"Blinded interim data from our ongoing Phase 2 RENEW trial provide an initial look at the safety, tolerability, and lung function trends observed across the study population. The improvement in FVC from baseline in 33% of evaluable patients is particularly encouraging, as improvements in lung function are unexpected in this patient population. In addition to the lung function improvements we are seeing in the study, adverse events across all patients were mild to moderate in severity, with no serious adverse events attributed to the drug, and a low discontinuation rate, with 92% of participants remaining in or having completed the study. While the study remains blinded, these observations collectively strengthen our belief that LTI-03 has the potential to transform the treatment landscape for IPF," said Cory Hogaboam, Ph.D., Chief Scientific Officer.

Third Quarter 2026 Financial Results
Cash position: As of September 30, 2026, cash, cash equivalents, and marketable securities were $36.5 million. As of September 30, 2026, the company's cash, cash equivalents, and marketable securities are expected to fund operations into the first quarter of 2028 to complete the Phase 2 RENEW clinical trial of LTI-03.

Research and development expenses: Research and development expenses were $4.4 million for the quarter ended September 30, 2026, compared to $1.7 million for the same period in the prior year. The $2.7 million increase was primarily due to increased spending on the Phase 2 RENEW clinical trial compared to the prior year, during which the FDA had placed a clinical hold on LTI-03 that was lifted in October 2025.

General and administrative expenses: General and administrative expenses were $2.6 million for the quarter ended September 30, 2026, compared to $3.8 million for the same period in the prior year. The decrease was primarily due to lower professional fees.

Net loss: Net loss was $5.5 million for the quarter ended September 30, 2026, compared to $5.6 million for the same period in the prior year.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements made by Rein Therapeutics, Inc. pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the development of LTI-03, the design, conduct, and expected results of the Phase 2 RENEW trial, the potential clinical benefits of LTI-03, future development milestones, and the company's financial resources. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "might," "should," "continue," and similar terms and expressions to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including: the risk that the company may not successfully continue its Phase 2 clinical trial of LTI-03; the risk that the company may not report topline data from its Phase 2 trial in 2027, or that if it does, such data may not support or validate our expectations regarding the potential benefits of LTI-03; the risk that success in preclinical studies and early-stage clinical trials does not ensure that later-stage clinical trials will be successful; the risk that preliminary blinded interim observations may not predict subsequent or final study results; the lung function observations described in this press release are pooled across randomized treatment groups and cannot establish efficacy, dose response, or superiority over placebo; the 5.7% FVC decline threshold is descriptive and not a validated measure of 12-week treatment response; preliminary adverse event causality assessments may change as more data become available; and the risk that the company's current cash and cash equivalents may not be sufficient to support the company's operations into the first quarter of 2028, as well as other risks disclosed in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, and in the company's subsequent filings with the SEC. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Rein Therapeutics Investor Relations and Media Contact:
Investor Relations
IR@ReinTx.com

REIN THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
September 30, 2026 December 31, 2025
Assets
Current assets:
Cash and cash equivalents $ 943 $ 3,215
Short-term investments 34,550 —
Prepaid expenses and other current assets 1,292 1,111
Total current assets 36,785 4,326
Goodwill 6,330 6,330
Intangible assets 13,500 13,500
Long-term investments 994 —
Other non-current assets 1,821 2
Total assets $ 59,430 $ 24,158
Liabilities, Convertible Preferred Stock, and Stockholders' Equity
Current liabilities:
Accounts payable $ 3,199 $ 3,976
Accrued expenses and other current liabilities 2,399 2,204
Total current liabilities 5,598 6,180
Deferred tax liabilities 1,060 1,060
Total liabilities 6,658 7,240
Commitments and contingencies
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized at September 30, 2026 and December 31, 2025; 24,610 shares issued and 12,232 shares outstanding at September 30, 2026 and December 31, 2025 45,005 45,005
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 and 100,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 86,267,032 and 27,550,222 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively 172 113
Additional paid-in capital 426,731 373,133
Accumulated other comprehensive loss
Accumulated deficit
Total liabilities, convertible preferred stock, and stockholders' equity $ 59,430 $ 24,158

REIN THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
Three Months Ended September 30, Nine Months Ended September 30,
2026 2025 2026 2025
Revenue $ — $ — $ — $ —
Operating expenses:
Research and development 4,375 1,681 11,086 9,028
General and administrative 2,624 3,811 7,219 8,944
Total operating expenses 6,999 5,492 18,305 17,972
Loss from operations
Other income, net 1,462 555 68
Net loss $ $ $ $
Net loss per share—basic and diluted $ $ $ $
Weighted-average common shares outstanding—basic and diluted 88,325,917 26,361,386 62,134,091 24,171,173
Comprehensive loss:
Net loss $ $ $ $
Other comprehensive loss:
Unrealized gain on investments, net of tax of $0 —
Foreign currency translation adjustment — 4 7
Total other comprehensive loss —
Total comprehensive loss $ $ $ $
Photos accompanying this announcement are available at

Original: https://www.globenewswire.com/news-release/2026/11/16/3403389/28652/en/rein-therapeutics-announces-preliminary-blinded-phase-2-renew-data-showing-encouraging-lung-function-trends-in-patients-with-idiopathic-pulmonary-fibrosis-and-reports-third-quarter.html

insigtX content is informational and educational, not investment advice.